Bayer's Two-Front Recovery: Drought-Proof Wheat and a Legal Clock That Keeps Sliding
Published on 08/19/2026 at 18:12 | Redaktion boerse-global.de
The summer drought of 2026 is doing something unusual to Bayer's agricultural arm: it is squeezing the crop-protection business while simultaneously seeding what analysts believe could become a €1 billion wheat-seed opportunity. Farmers in parched regions are tightening spending on chemicals, yet their demand for varieties that can withstand water scarcity is climbing — a structural shift that could outlast the current heatwave.
For the Leverkusen-based group, the weather presents a genuinely mixed picture. Crop Science derives a substantial share of its revenue from the pesticides business, which now faces softer investment appetite from farmers. But the seed segment is emerging as the counterweight, with climate-resilient wheat potentially evolving into a durable growth engine rather than a seasonal blip.
That backdrop frames a company already showing operational momentum. Second-quarter results, published just over a week ago, lifted the shares by 2.6 percent since then. The US re-approval of Dicamba drove a 3.5 percent revenue increase in the Crop Science division, while management reaffirmed its full-year guidance: currency-adjusted sales growth of 1.5 percent and core earnings per share of approximately €4.55.
While agricultural businesses plan for climate-driven shifts, workplace safety planning deserves the same forward-thinking approach. Many employers underestimate how quickly gaps in risk documentation can become costly liabilities. A free toolkit with 41 ready-to-use checklists and templates helps you document hazards and protect your team. Download the free Risk Assessment Toolkit
The Legal Calendar Keeps Moving
Investors, however, have learned to keep one eye on the courtroom. The Missouri court overseeing the Roundup class-action settlement has pushed the hearing for final approval from the originally scheduled August 19 to September 14. The reason is procedural rather than substantive: additional time is needed to process opt-out requests from plaintiffs. Both Monsanto and the plaintiffs' attorneys jointly requested the delay, which suggests coordination rather than conflict.
The postponement lands in a context of gradual legal de-risking. The US Supreme Court's ruling in the Durnell case, which favored Monsanto, has been widely read as a meaningful step toward a more contained liability picture. Against that backdrop, the September date looks less like a fresh source of anxiety and more like a checkpoint on the road to resolving a long-standing overhang.
A Share Price Rebuilding Its Base
The market's response to this combination of operational steadiness and receding legal fog has been a measured recovery. The stock trades at €49.22, roughly 6.3 percent above its 50-day moving average of €46.30 — evidence that the recent advance has broad support. Still, the shares sit 8.6 percent below their 52-week high of €53.86, touched in early July.
The valuation debate, meanwhile, has produced a striking spread among analysts. JPMorgan raised its target to €61, UBS to €62, and Goldman Sachs to €63.50, all with bullish ratings. Deutsche Bank holds at €60. Jefferies, by contrast, maintains a "Hold" with a target of just €46 — barely above the current price. The gap reflects how much hinges on the September hearing actually delivering a confirmed settlement rather than another adjournment.
As companies navigate regulatory scrutiny, ensuring compliance with workplace safety laws is equally critical. Over 37,000 UK businesses already rely on a free toolkit covering everything from fire safety to COSHH compliance. Protect your workforce and stay on the right side of regulators with ready-to-use templates. Get the free Health & Safety Toolkit
The CEO's Bet on Organic Value
Chief executive Bill Anderson has staked his strategy on the premise that Bayer does not need to be broken apart to create value. Two weeks ago, he explicitly ruled out a split of the conglomerate's pharma, crop science, and consumer health units "for now," arguing that the company is strategically stronger than in previous restructuring debates.
That conviction rests on three pillars: accelerating debt reduction, organic growth in the core businesses, and selective pipeline wins. The net financial debt outlook for 2026 has been raised to €29–30 billion — a signal that deleveraging is tracking ahead of expectations. In pharma, China's acceptance of the regulatory review for Aflibercept 8 mg, targeting macular edema following retinal vein occlusion, offers a modest but concrete validation of the research pipeline.
The bear case is equally coherent. The Roundup hearing has now been postponed twice — once at Bayer's own request, once by the court. Each delay feeds skepticism about whether the proposed $7.25 billion settlement will ever receive final approval. If the legal picture remains unresolved, the market is unlikely to discount the risk premium that has weighed on the stock, and some of the recent target hikes could prove premature.
What Comes Next
The immediate calendar offers two fixed points: the Missouri hearing on September 14 and the third-quarter results scheduled for November 3. Between now and then, the drought story will likely remain a secondary narrative — relevant for the quarters ahead, but not the dominant driver of the share price.
The bigger question is whether Anderson's refusal to consider a breakup will hold up if organic growth stumbles. For now, the combination of falling debt, operational stabilization, and a legal process that appears to be moving — however slowly — toward closure supports a constructive outlook. But the September date is the fulcrum: if it passes without further slippage and delivers a confirmed settlement, the path toward the more optimistic analyst targets becomes credible. If it slips again, the old uncertainties will resurface with renewed force.
